Molecule 10

Molecule 10 is an experimental small molecule candidate identified through an integrated bioinformatics and computational chemistry pipeline for the treatment of breast cancer. Discovered via high-throughput virtual screening and lead optimization, Molecule 10 was selected for its high binding affinity to key therapeutic targets, such as the Estrogen Receptor alpha (ERα) or HER2, which are central to the progression of various breast cancer subtypes. Computational modeling, including molecular docking and molecular dynamics simulations, suggests that Molecule 10 possesses favorable drug-like properties and the potential to disrupt oncogenic signaling pathways. As a lead compound identified in preclinical in silico studies, it serves as a scaffold for further medicinal chemistry optimization and biological validation as a targeted antitumor agent.